OCEA: Ocean Bio Price to Sales
Ocean Biomedical, Inc. (OCEA) is developing a closed patent loop to combat malaria and cancer. This chart on GURU.Markets shows that the price-to-sales ratio has reached the metric. The business model relies on the commercialization of university research and the production of vaccines. However, a lack of internal revenue and the depletion of reserves force the company to regularly seek third-party investment.
Analytical breakdowns for Ocean Bio (OCEA)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Debt to Capital Ocean Biomedical, Inc.|OCEA - Long-Term Debt to Capital|Short-Term Debt to Capital Ocean Biomedical Corp|OCEA - Company Debts|Debt to Book Value Ratio Ocean Bio|OCEA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Ocean Biomedical|Quick Liquidity oceanbiomedical.com
- earnings and multiples data:
OCEA - Net Profit|Company Profit Forecast Ocean Biomedical, Inc.|OCEA - Price to Earnings Ratio|Projected Price to Earnings Ratio Ocean Biomedical Inc|OCEA - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Ocean Bio|OCEA - Operating profit EBITDA|Net earnings per one share for the last twelve months Ocean Biomedical|OCEA - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months oceanbiomedical.com|OCEA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Ocean Biomedical, Inc.
- issuer revenue and sales details:
Fundamental company analysis:oceanbiomedical.com (OCEA)
Analyzing the scale of Ocean Biomedical, Inc. (OCEA) through changes in the price-to-sales ratio allows for a comparison of the business's market value with actual sales volume. This metric links market capitalization to revenue and debt load, revealing asset overheating or liquidity risks, which is critical for biopharmaceuticals amid sanction threats to raw material supply chains and the complexities of foreign patent protection.
Who Ocean Biomedical, Inc. competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Price to Sales Protagonist Corp|IMVT: P/S Multiple|Market Cap to Revenue kiniksa.com|GRFS (Grifols) - P/S Multiple|Price to Sales Adaptive Biotech ADPT|P/S Multiple CLDX|P/S Multiple Aurinia Corp (AUPH)|Price-to-Revenue Ratio BioCryst BCRX|VERA: Market Cap to Revenue Ratio|DNTH: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PHVS (Pharvaris NV)|ABCL: P/S Multiple|TRML (Tourmaline) - Price-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|pharming.com (PHAR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|UPB - Price to Sales|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|IMNM - Market Cap to Revenue|Gossamer Bio, Inc. - P/S Multiple|Price to Sales kalvista.com|SEPN: P/S Multiple|Market Cap to Revenue Ratio PVLA|SVRA (Savara Corp) - P/S Multiple|Rigel Corp (RIGL) - Price-to-Revenue Coefficient|P/S Multiple ANAB|Market Cap to Revenue astriatx.com ATXS|P/S Multiple ENGN (enGene)|P/S Multiple RAPT Therapeutics Inc. RAPT|JBIO - Price-to-Revenue Ratio|ACRS: Price-to-Revenue Ratio|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|tizianalifesciences.com - Market Capitalization-to-Revenue Ratio|CABA (Cabaletta Bio) - P/S Multiple|Ventyx Biosciences Inc. (VTYX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Theratechnologies Inc (THTX)|Avalo Therapeutics Inc - Market Cap to Revenue Ratio|P/S Multiple ELDN (Eledon Pharmaceuticals)|AGEN - Market Cap to Revenue|CLYM: Market Cap to Revenue|Price-to-Revenue Coefficient Zura Bio Ltd ZURA|aTyr (ATYR) - Price-to-Revenue Ratio|Price to Sales Adagene Inc. (ADAG)|IMA (ImageneBio) - P/S Multiple|Market Cap to Revenue Shattuck Therapeutics (STTK)|P/S Multiple EQ|CNTB - Price to Sales|P/S Multiple IMUX (Immunic)|P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX - Price-to-Revenue Ratio|Price-to-Sales Ratio XFOR|ACET: P/S Multiple|Celularity - Market Capitalization-to-Revenue Ratio|INMB (INmune Bio Corp) - P/S Multiple|P/S Multiple Barinthus Biotherapeutics Corp|Price-to-Revenue Ratio Kezar Life Sciences (KZR)|SABS (sabbiotherapeutics.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Akari Therapeutics Plc AKTX|ENLV - Market Cap to Revenue|Q32 Bio Corp - P/S Multiple|GOVX - P/S Multiple|EDSA (Edesa Biotech, Inc.) - Market Cap to Revenue|ibioinc.com - Market Capitalization-to-Revenue Ratio|CARM (Carisma Therapeutics Inc) - P/S Multiple|XTL Biopharmaceuticals Ltd (XTLB) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Bolt Biotherapeutics (BOLT)|Market Cap to Revenue hcwbiologics.com HCWB|Price-to-Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM - Market Cap to Revenue|ADTX: Market Cap to Revenue|GRI - P/S Multiple|XORTX (XRTX) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio HIND|REVB (Revelation Biosciences) - P/S Multiple|Price to Sales indaptusrx.com INDP|Price-to-Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI - Price to Sales|P/S Multiple AFMD (Affimed N.V.)|ALLK - Market Cap to Revenue|HOOKIPA - P/S Multiple|Price to Sales IGM Biosciences, Inc.|ITOS: P/S Multiple|TC BioPharm (Holdings) Plc (TCBP) - P/S Multiple|Price-to-Revenue Ratio Third Harmonic Bio, Inc
